Serum levels of carcinoembryonic antigen (CEA) in patients with bipolar disorder. 2015

Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
1Department of Biochemistry, Medical Faculty,Dicle University,Diyarbakır,Turkey.

OBJECTIVE Carcinoembryonic antigen (CEA) is an oncofetal glycoprotein that is widely used as a tumour marker in adenocarcinomas. However, several non-neoplastic conditions, including acute and chronic inflammation and other inflammation-related conditions, are characterised by increased CEA concentrations. Bipolar disorder (BD) ranks seventh among the worldwide burden of non-fatal diseases. Inflammatory biomarkers have been considered as one of the main key pillars of a multifactorial approach for prediction of BD in an at-risk population. BP is accompanied by activation of inflammatory, cell-mediated and negative immunoregulatory cytokines. METHODS We measured the levels of CEA in serum samples from 44 individuals with euthymic BP out-patients and 45 healthy controls. Patients were diagnosed according to the DSM-IV criteria. CEA was measured by an electrochemiluminescence immunoassay. RESULTS The mean serum CEA concentration was 2.36±1.52 and 1.77±0.98 µg/l in patients and controls, respectively. CEA levels were significantly increased in euthymic BP patients when compared with controls (p=0.031). CONCLUSIONS This study suggests that CEA is increased in BD and supports a role for immune activation in the core pathological mechanisms of BP. CEA levels may be a secondary marker for diagnosing BP.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D008297 Male Males
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001714 Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. Affective Psychosis, Bipolar,Bipolar Disorder Type 1,Bipolar Disorder Type 2,Bipolar Mood Disorder,Depression, Bipolar,Manic Depression,Manic Disorder,Manic-Depressive Psychosis,Psychosis, Manic-Depressive,Type 1 Bipolar Disorder,Type 2 Bipolar Disorder,Psychoses, Manic-Depressive,Bipolar Affective Psychosis,Bipolar Depression,Bipolar Disorders,Bipolar Mood Disorders,Depression, Manic,Depressions, Manic,Disorder, Bipolar,Disorder, Bipolar Mood,Disorder, Manic,Manic Depressive Psychosis,Manic Disorders,Mood Disorder, Bipolar,Psychoses, Bipolar Affective,Psychoses, Manic Depressive,Psychosis, Bipolar Affective,Psychosis, Manic Depressive
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
January 1985, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
January 1979, Acta neurochirurgica,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
February 1988, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
July 1987, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
February 1978, The American journal of digestive diseases,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
January 1973, Digestion,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
January 1998, Otolaryngologia polska = The Polish otolaryngology,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
January 1976, Immunochemistry,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
December 1984, Quaderni Sclavo di diagnostica clinica e di laboratorio,
Ibrahim Kaplan, and Mahmut Bulut, and Abdullah Atli, and Mehmet Güneş, and Mehmet Cemal Kaya, and Leyla Çolpan
August 1976, European journal of cancer,
Copied contents to your clipboard!